Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Metabolic Health

Type 1 Diabetes Is a Barrier to Obesity Treatment: Patient Insights From a Mixed-Methods Study

Al Ozairi E, Alsaeed D, Mondoh A, Taghadom E, Irshad M, Alroudhan D, Kandari JA, Al-Najim W, le Roux CW. Type 1 Diabetes Is a Barrier to Obesity Treatment: Patient Insights From a Mixed-Methods Study J Obes
Insulin Resistance & Diabetes

Beyond BMI: Practical Guide for Clinicians to Integrate the Lancet Commission’s Obesity Framework and King’s Obesity Staging System

Ko TYL, Miras AD, Pournaras DJ, Le Roux CW. Beyond BMI: Practical Guide for Clinicians to Integrate the Lancet Commission’s Obesity Framework and King’s Obesity Staging System Clin Obes
Body composition

Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study

Ozairi EA, Taghadom E, Irshad M, Yousef AA, AlKandari J, Al-Najim W, Alabdulkader S, Miras AD, le Roux CW. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study Diabetes Res Clin Pract
Insulin Resistance & Diabetes

Metabolic and appetitive regulation of adipocyte mass during treatment of obesity

Purnell JQ, Le Roux CW. Metabolic and appetitive regulation of adipocyte mass during treatment of obesity J Intern Med

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme

Pandey A, Moroney M, Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Petrie MC, Rönnbäck C, Domdey A, Rasmussen S, Chinnakondepalli KM, Patel S, Kosiborod MN. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme Eur J Heart Fail

Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial

Platz E, Kaplan LM, le Roux CW, Wharton S, Burger S, Hussain SA, Brueckmann M, Startseva E, Fey C, Kosiborod MN, Bozkurt B. Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial JACC Heart Fail
Chronic Kidney Disesae

Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document

Monzo L, Savarese G, Mullens W, Abdin A, Bozkurt B, Chioncel O, El Hadidi S, Gorter TM, Inciardi RM, Petrie MC, Schiattarella GG, Stolfo D, Metra M, Girerd N. Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document Eur J Heart Fail

Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity

Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity Endocr Rev
Insulin Resistance & Diabetes

Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease

Sedrak P, Verma R, Verma M, Connelly KA. Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease The Canadian Journal of Cardiology

Metallomic profiles of pregnant women living with obesity in the UK: a secondary analysis of UPBEAT

Agostinho de Sousa J, Griffiths A, Dalrymple KV, White SL, von Meyenn F, Poston L, Rigutto-Farebrother J, Flynn AC. Metallomic profiles of pregnant women living with obesity in the UK: a secondary analysis of UPBEAT Metallomics

Older posts

Page1 Page2 … Page56 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI